Thailand's GPO Head Says Fixing Low-Yield H1N1 Vaccine Problem
This article was originally published in PharmAsia News
The head of Thailand's Government Pharmaceutical Organization said the company now has enough eggs to grow the H1N1 flu virus and make a vaccine against the disease. GPO Chairman Vichai Chokevivat said he expects to produce the amount of vaccine as originally intended. The first batch of eggs produced a low yield of the live attenuate virus the GPO had been relying on, but a new batch obtained from elsewhere is being counted on to produce a normal yield. (Click here for more
You may also be interested in...
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.
Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand.